SCHEMBL1406240

SCHEMBL1406240

CCOC(=O)c1cc2ccc(O)cc2oc1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 4/20 1.00
PFKFB3 Q16875 1/20 1.00
MAOB P27338 9/20 0.80
MAOA P21397 3/20 0.80
KDM4E B2RXH2 5/20 0.72
GLA P06280 4/20 0.72
GAA P10253 4/20 0.72
ALDH1A1 P00352 3/20 0.72
HPGD P15428 3/20 0.72
CA12 O43570 2/20 0.72
CA2 P00918 2/20 0.72
CA3 P07451 2/20 0.72
CA4 P22748 2/20 0.72
CA6 P23280 2/20 0.72
CA7 P43166 2/20 0.72
CA9 Q16790 2/20 0.72
CA14 Q9ULX7 2/20 0.72
MAPT P10636 3/20 0.66
HSD17B10 Q99714 2/20 0.66
TP53 P04637 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29399552 1.00 MIF (1.00) MIFPFKFB3MAOBMAOAKDM4E
SCHEMBL30267263 0.95 MIF (0.90) MIFPFKFB3MAOBMAOAKDM4E
SCHEMBL6417829 0.89 MAOB (1.00) MIFPFKFB3MAOBMAOAKDM4E
SCHEMBL10855650 0.88 MIF (0.77) MIFPFKFB3MAOBMAOAKDM4E
SCHEMBL12611191 0.87 MIF (0.78) MIFPFKFB3MAOBMAOAKDM4E
SCHEMBL10789548 0.86 MIF (0.73) MIFPFKFB3MAOBMAOAKDM4E
SCHEMBL11595332 0.85 MIF (0.74) MIFPFKFB3MAOBMAOAKDM4E
SCHEMBL21585388 0.85 MIF (0.74) MIFPFKFB3MAOBMAOAKDM4E
SCHEMBL11492411 0.85 MIF (0.74) MIFPFKFB3MAOBMAOAKDM4E
SCHEMBL592309 0.85 MIF (0.73) MIFPFKFB3MAOBMAOAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630638-B2 Methods and compositions for diabetes treatment and β-cell regeneration THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-05-19 US claimed
US-20250017950-A1 COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS UCL BUSINESS LTD (GB) 2025-01-16 US claimed
EP-4433077-A1 COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS UCL Business Ltd (GB) 2024-09-25 EP claimed
US-20230165965-A1 NEW COUMARIN-POLYMER CONJUGATES AND USES THEREOF ONYEL BIOTECH S.R.L. (IT) 2023-06-01 US claimed
WO-2023089313-A1 COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS UCL BUSINESS LTD (GB) 2023-05-25 WO claimed
CN-107446015-B Coumarin derivative and preparation method and application thereof 首都医科大学 2020-10-16 CN claimed
EP-2516666-B1 METHODS OF DETECTING MICROORGANISMS AND KITS THEREFORE 3M INNOVATIVE PROPERTIES CO (US) 2016-04-20 EP claimed
EP-2718458-B1 NOVEL METHOD FOR DETECTION OF BETA-D-GLUCURONIDASE BIOSYNTH AG (CH) 2015-07-08 EP claimed
US-20140212905-A1 Novel Method for Detection of Beta-D-Glucuronidase BIOSYNTH AG (CH) 2014-07-31 US claimed
EP-2718458-A1 NOVEL METHOD FOR DETECTION OF BETA-D-GLUCURONIDASE Biosynth AG (CH) 2014-04-16 EP claimed
US-8518664-B2 Methods of determining the amount of microorganisms present in a test sample 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-08-27 US claimed
WO-2012168415-A1 NOVEL METHOD FOR DETECTION OF BETA-D-GLUCURONIDASE BIOSYNTH AG (CH) 2012-12-13 WO claimed
EP-2532753-A1 Method for detection of beta-D-glucuronidase Biosynth AG (CH) 2012-12-12 EP claimed
US-20120302631-A1 Inhibitors of PFKFB3 for Cancer Therapy BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE 2012-11-29 US claimed
EP-2516666-A1 METHODS OF DETECTING MICROORGANISMS AND KITS THEREFORE 3M Innovative Properties Company (US) 2012-10-31 EP claimed
US-20120252049-A1 METHODS OF DETECTING MICROORGANISMS AND KITS THEREFORE 3M INNOVATIVE PROPERTIES COMPANY 2012-10-04 US claimed
WO-2011087711-A1 METHODS OF DETECTING MICROORGANISMS AND KITS THEREFORE 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-07-21 WO claimed
US-12630638-B2 Methods and compositions for diabetes treatment and β-cell regeneration THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-05-19 US disclosed
US-4279992-A Specific binding assay employing an enzyme-cleavable substrate as label MILES LABORATORIES, INC. (US) 1981-07-21 US disclosed
US-4151291-A ANALGESICS UNICLER (FR) 1979-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230165965-A1 NEW COUMARIN-POLYMER CONJUGATES AND USES THEREOF CBR3, CYP3A43, CYP3A4 MIF 2404/4885PFKFB3 850/4885MAOB 3648/4885
US-20120302631-A1 Inhibitors of PFKFB3 for Cancer Therapy PFKFB3, PFKFB2, PFKFB1 MIF 4491/4885PFKFB3 1/4885MAOB 2055/4885
US-12630638-B2 Methods and compositions for diabetes treatment and β-cell regeneration IAPP, APP, SLC2A3 MIF 3464/4885PFKFB3 27/4885MAOB 2636/4885
US-20250017950-A1 COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS POLRMT, TK2, GOT2 MIF 4875/4885PFKFB3 485/4885MAOB 3590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.